Oral adverse drug reactions to cardiovascular drugs

Critical Reviews in Oral Biology and Medicine

Volumn 15, Issue 1, 2004, Pages 28-46

  Torpet, Lis Andersen ^a   Kragelund, Camilla ^a   Reibel, Jesper ^a   Nauntofte, Birgitte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CYP; Drug interaction; Medication; Oral mucous membrane; Therapeutic classes

Indexed keywords

EID: 7044248423     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130401500104     Document Type: Review

References (139)

1. Abernethy DR, Flockhart DA (2000). Molecular basis of cardiovascular drug metabolism-implications for predicting clinically important drug interactions. Circulation 101:1749-1753.
2. Acker CG, Greenberg A (1995). Angioedema induced by the angiotensin II blocker losartan (letter). N Engl J Med 333:1572.
3. Agostoni A, Cicardi M (2001). Drug-induced angioedema without urticaria. Drug Safety 24:599-606.
4. Ameyaw MM, Syvänen AC, Ulmanen I, Ofori-Adjei D, McLeod HL (2000). Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Hum Mutat 16:445-446.
5. Aparasu RR (1999). Visits to office-based physicians in the United States for medication-related morbidity. J Am Pharm Assoc (Wash) 39:332-337.
6. Apaydin R, Bilen N, Dokmeci S, Bayramgurler D, Yildirim G (2000). Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital. J Eur Acad Dermatol Venereol 14:518-520.
7. Aster RH (2000). Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 37:229-238.
8. Baum B, Ferguson M, Fox P, Johansson I, Marmary Y, Nauntofte B, et al. (2000). Medication-induced salivary gland dysfunction. In: Perspectives on the 3rd World Workshop on Oral Medicine. Millard HD, Mason DK, editors. Ann Arbor, MI: BMC Media Services, pp. 288-292.
9. Becker DS (1998). Toxic epidermal necrolysis. Lancet 351:1417-1420.
10. Bernini F, Poli A, Paoletti R (2001). Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 15:211-218.
11. Bigby M, Jick S, Jick H, Arndt K (1986). Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. J Am Med Assoc 256:3358-3363.
12. Birek C, Main JH (1988). Two cases of oral pigmentation associated with quinidine therapy. Oral Surg Oral Med Oral Pathol 66:59-61.
13. Blaufarb I, Pfeifer TM, Frishman WH (1995). Beta-blockers. Drug interactions of clinical significance. Drug Safety 13:359-370.
14. Boulinguez S, Reix S, Bedane C, Debrock C, Bouyssou-Gauthier ML, Sparsa A, et al. (2000). Role of drug exposure in aphthous ulcers: a case-control study. Br J Dermatol 143:1261-1265.
15. Boxer M (1996). Accupril- and Cozaar-induced angioedema in the same patient (letter). J Allergy Clin Immunol 98:471.
16. Brenner S, Bialy-Golan A, Ruocco V (1998). Drug-induced pemphigus. Clin Dermatol 16:393-397.
17. Brinn R, Brosen K, Gram LF, Haghfelt T, Otton SV (1986). Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22:194-197.
18. Brooks SL (1982). Lichenoid reaction of oral mucosa and skin to methyldopa. J Oral Med 37:42-44.
19. Brosnan BD, Frishman WH, Sun DK, Grossman M (2000). Adverse dermatologic effects of cardiovascular drug therapy. Heart Dis 2:220-247.
20. Brown FH, Houston GD, Phillips M, Westbrook SD (1989). Erythema multiforme following cardizem therapy: report of a case. Ann Dent 48:39-40, 52.
21. Brown RS, Beaver WT, Bottomley WK (1991). On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med 20:201-209.
22. Brown RS, Krakow AM, Douglas T, Choksi SK (1997). "Scalded mouth syndrome" caused by angiotensin converting enzyme inhibitors: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83:665-667.
23. Bullon P, Machuca G, Martinez-Sahuquillo A, Rios JV, Rojas J, Lacalle JR (1994). Clinical assessment of gingival hyperplasia in patients treated with nifedipine. J Clin Periodontol 21:256-259.
24. Burches E, Garcia-Verdegay F, Ferrer M, Pelaez A (2000). Amiodarone-induced angioedema. Allergy 55:1199-1200.
25. Burry JN, Kirk J (1974). Lichenoid drug reaction from methyldopa (letter). Br J Dermatol 91:475-476.
26. Camilleri M, Pace JL (1998). Drug-induced linear immunoglobulin-A bullous dermatosis. Clin Dermatol 16:389-391.
27. Caron J, Libersa C (1997). Adverse effects of class I antiarrhythmic drugs. Drug Safety 17:8-36.
28. Cohen DM, Bhattacharyya I, Lydiatt WM (1999). Recalcitrant oral ulcers caused by calcium channel blockers: diagnosis and treatment considerations. J Am Dent Assoc 130:1611-1618.
29. Corone S, Davido A, Corone P (1987). Une complication rare du captopril: l'ulceration des muqueuses linguales et jugales. Rev Med Interne 8:73-74.
30. Council for International Organizations of Medical Sciences (1998). Definitions and basic requirements for the use of terms for reporting adverse drug reactions (X); gastrointestinal system disorders. Pharmacoepidemiol Drug Safety 7:281-287.
31. Cox NH, Tapson JS, Farr PM (1989). Lichen planus associated with captopril: a further disorder demonstrating the 'tin-tack' sign. Br J Dermatol 120:319-321.
32. Crowson AN, Magro CM (1999). Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 17:537-60, viii.
33. Daoud MS, Schanbacher CF, Dicken CH (1998). Recognizing cutaneous drug eruptions. Reaction patterns provide clues to causes. Postgrad Med 104:101-8, 114.
34. Darwaza A, Lamey PJ, Connell JM (1988). Hydrallazine-induced Sjögren's syndrome. Int J Oral Maxillofac Surg 17:92-93.
35. Dellinger TM, Livingston HM (1998). Aspirin burn of the oral cavity (case). Ann Pharmacother 32:1107.
36. Dougall HT, McLay J (1996). A comparative review of the adverse effects of calcium antagonists. Drug Safety 15:91-106.
37. Dunn N, Freemantle S, Pearce G, Wilton LV, Mann RD (1999).Safety profile of nicorandil-prescription-event monitoring (PEM) study. Pharmacoepidemiology Drug Safety 8:197-205.
38. Edwards IR, Aronson JK (2000). Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255-1259.
39. Evans WE, Relling MV (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
40. FDA Code of Federal Regulation (1995). [21CFR 201.57(g)] (Available at www.fda.gov/cder).
41. Felix RH, Ive FA, Dahl MG (1974). Cutaneous and ocular reactions to practolol. Br Med J 4:321-324.
42. Firth NA, Reade PC (1989). Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 67:41-44.
43. Fugh-Berman A (2000). Herb-drug interactions. Lancet 355:134-138.
44. Gruchalla RS (2000). Clinical assessment of drug-induced disease. Lancet 356:1505-1511.
45. Hallmon WW, Rossmann JA (1999). The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000 21:176-196.
46. Hawk JL (1980). Lichenoid drug eruption induced by propanolol. Clin Exp Dermatol 5:93-96.
47. Hay KD, Reade PC (1978). Methyldopa as a cause of oral mucous membrane reactions. Br Dent J 145:195-203.
48. Hebert AA, Ralston JP (2001). Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 62(Suppl 14):22-26.
49. Hedner T, Samuelsson O, Lindholm L, Andren L, Wiholm BE (1991). Precipitation of angioedema by antihypertensive drugs. J Hypertens Suppl 9:S360-S361.
50. Hess DA, Rieder MJ (1997). The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann Pharmacother 31:1378-1387.
51. Hofstra AH (1994). Metabolism of hydralazine: relevance to drug-induced lupus. Drug Metab Rev 26:485-505.
52. Ingelman-Sundberg M (2001). Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250:186-200.
53. Jaffe IA (1986). Adverse effects profile of sulfhydryl compounds in man. Am J Med 80:471-476.
54. Jain VK, Dixit VB, Archana Dr (1991). Fixed drug eruption of the oral mucous membrane. Ann Dent 50:9-11.
55. Janmohamed A, Dolphin CT, Phillips IR, Shephard EA (2001). Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777-786.
56. Kaufman DW, Kelly JP, Jurgelon JM, Anderson T, Issaragrisil S, Wiholm BE, et al. (1996). Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 60:23-30.
57. Kawashima Z, Flagg RH, Cox DE (1975). Aspirin-induced oral lesion: report of case. J Am Dent Assoc 91:130-131.
58. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NP, Breimer DD (1984). Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 33:3721-3724.
59. Knowles S, Gupta AK, Shear NH (1998). The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. J Am Acad Dermatol 38:201-206.
60. Knowles SR, Uetrecht J, Shear NH (2000). Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 356:1587-1591.
61. Korkij W, Soltani K (1984). Fixed drug eruption. A brief review. Arch Dermatol 120:520-524.
62. Korman NJ, Eyre RW, Zone J, Stanley JR (1991). Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 96:273-276.
63. Kowalski BJ, Cody RJ (1997). Stevens-Johnson syndrome associated with carvedilol therapy. Am J Cardiol 80:669-670.
64. Kragelund C, Thomsen CE, Bardov A, Pedersen AM, Nauntofte B, Reibel J, et al. (2003). Oral lichen planus and intake of drugs metabolised by polymorphic cytochrome P450. Oral Dis 9:177-187.
65. Kubo SH, Cody RJ (1984). Enalapril, a rash, and captopril (letter). Ann Intern Med 100:616.
66. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-94.
67. Lamey PJ, Gibson J, Barclay SC, Miller S (1990). Grinspan's syndrome: a drug-induced phenomenon? Oral Surg Oral Med Oral Pathol 70:184-185.
68. Lamey PJ, McCartan BE, MacDonald DG, MacKie RM (1995). Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:44-49.
69. Langtry HD, Markham A (1997). Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 10:131-166.
70. Laurence DR (1998). A dictionary of pharmacology and allied topics. Amsterdam: Oxford Elsevier.
71. Lawton G, Paciorek PM, Waterfall JF (1992). The design and biological profile of ACE inhibitors. Adv Drug Res 23:161-220.
72. Maier C (1995). [Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor]. Anaesthetist 44:875-879.
73. Mansur AP, Avakian SD, Paula RS, Donzella H, Santos SR, Ramires JA (1998). Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. Braz J Med Biol Res 31:691-696.
74. Marquart-Elbaz C, Lipsker D, Grosshans E, Cribier B (1999). [Oral ulcers induced by nicorandil: prevalence and clinicopathological aspects]. Ann Dermatol Venereol 126:587-590.
75. Marshall RI, Bartold PM (1998). Medication induced gingival overgrowth. Oral Dis 4:130-151.
76. McGovern B, Garan H, Kelly E, Ruskin JN (1983). Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 287:175-180.
77. Mehregan DR, Mehregan DA, Pakideh S (1998). Cheilitis due to treatment with simvastatin. Cutis 62:197-198.
78. Messerli FH, Nussberger J (2000). Vasopeptidase inhibition and angio-oedema. Lancet 356:608-609.
79. Moore N (2001). The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Safety 24:1-7.
80. Mott AE, Grushka M, Sessle BJ (1993). Diagnosis and management of taste disorders and burning mouth syndrome. Dent Clin North Am 37:33-71.
81. Nakagawa K, Ishizaki T (2000). Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther 86:1-28.
82. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, et al. (1999). Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 48:839-846.
83. Neville E, Graham PY, Brewis RA (1981). Orogenital ulcers, SLE and hydralazine. Postgrad Med J 57:378-379.
84. Nicholls MG, Maslowski AH, Ikram H, Espiner EA (1981). Ulceration of the tongue: a complication of captopril therapy (Brief report). Ann Intern Med 94:659.
85. Ozdemir V, Shear NH, Kalow W (2001). What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Safety 24:75-85.
86. Pedersen AM, Torpet LA, Reibel J, Holmstrup P, Nauntofte B (2002). Oral findings in patients with primary Sjögren's syndrome and oral lichen planus-a preliminary study on the effects of bovine colostrum-containing oral hygiene products. Clin Oral Invest 6:11-20.
87. Petrie JC, Galloway DB, Jeffers TA, Webster J (1976). Adverse reactions to beta-blocking drugs: a review. Postgrad Med J 52(Suppl 4):63-69.
88. Pinto GM, Lamarao P, Vale T (1992). Captopril-induced pemphigus vegetans with Charcot-Leyden crystals. J Am Acad Dermatol 27:281-284.
89. Pirmohamed M, Madden S, Park BK (1996). Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet 31:215-230.
90. Plosker GL, McTavish D (1995). Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Drugs Aging 7:226-253.
91. Porter SR, Scully C, Pedersen A (1998). Recurrent aphthous stomatitis. Crit Rev Oral Biol Med 9:306-321.
92. Pradalier A, Dry J, Baron JF (1982). Stomatite aphtoïde induite par le labétolol. Therapie 37:695-697.
93. Rees SR, Gibson J (1997). Angioedema and swellings of the orofacial region. Oral Dis 3:39-42.
94. Rees TD (1998). Drugs and oral disorders. Periodontol 2000 18:21-36.
95. Rendic S (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
96. Roberts JR, Wuerz RC (1991). Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med 20:555-558.
97. Roger D, Rolle F, Labrousse F, Brosset A, Bonnetblanc JM (1994). Simvastatin-induced lichenoid drug eruption. Clin Exp Dermatol 19:88-89.
98. Rosenthal T, Ezra D (1995). Calcium antagonists. Drug interactions of clinical significance. Drug Safety 13:157-187.
99. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R (1999). Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-controlstudy. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 353:2190-2194.
100. Sabroe RA, Black AK (1997). Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 136:153-158.
101. Sadick NS, Katz AS, Schreiber TL (1989). Angioedema from calcium channel blockers. J Am Acad Dermatol 21:132-133.
102. Sauve L, Gras-Champel V, Decocq G, Masson H, Andrejak M (1999). Angioedèmes associeés à la prise de dihydropyridines. Therapie 54:64-65.
103. Savino LB, Haushalter NM (1992). Lisinopril-induced "scalded mouth syndrome". Ann Pharmacother 26:1381-1382.
104. Scully C, Azul AM, Crighton A, Felix D, Field A, Porter SR (2001). Nicorandil can induce severe oral ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91:189-193.
105. Seedat YK (1979). Aphthous ulcers of mouth from captopril. Lancet 2:1297-1298.
106. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR (1994). Amlodipine-induced gingival overgrowth. J Clin Periodontol 21:281-283.
107. Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL, et al. (2000). Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Am J Med 109:489-492.
108. Shapiro LE, Shear NH (1996). Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 15:217-227.
109. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. (1988). Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. J Am Med Assoc 260:967-970.
110. Smith G, Stubbins MJ, Harries LW, Wolf CR (1998). Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129-1165.
111. Spielman AI (1998). Chemosensory function and dysfunction. Crit Rev Oral Biol Med 9:267-291.
112. Sreebny LM, Schwartz SS (1997). A reference guide to drugs and dry mouth, 2nd ed. Gerodontology 14:33-47.
113. Stern R, Khalsa JH (1989). Cutaneous adverse reactions associated with calcium channel blockers. Arch Intern Med 149:829-832.
114. Sun DK, Reiner D, Frishman W, Grossman M, Luftschein S (1994). Adverse dermatologic reactions from antiarrhythmic drug therapy. J Clin Pharmacol 34:953-966.
115. Svensson CK, Cowen EW, Gaspari AA (2001). Cutaneous drug reactions. Pharmacol Rev 53:357-379.
116. Swale VJ, McGregor JM (2001). Amlodipine-associated lichen planus. Br J Dermatol 144:920-921.
117. Thompson CC, Tacke RB, Woolley LH, Bartley MH (1982). Purpuric oral and cutaneous lesions in a case of drug-induced thrombocytopenia. J Am Dent Assoc 105:465-467.
118. Thompson DF, Skaehill PA (1994). Drug-induced lichen planus. Pharmacotherapy 14:561-571.
119. Tran C, Knowles SR, Liu BA, Shear NH (1998). Gender differences in adverse drug reactions. J Clin Pharmacol 38:1003-1009.
120. Trujillo TC, Nolan PE (2000). Antiarrhythmic agents: drug interactions of clinical significance. Drug Safety 23:509-532.
121. Uetrecht JP (1999). New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 12:387-395.
122. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J (1998). Angioneurotic edema attributed to the use of losartan. Arch Intern Med 158:2063-2065.
123. Vassileva S (1998). Drug-induced pemphigoid: bullous and cicatricial Clin Dermatol 16:379-387.
124. Vervloet D, Durham S (1998). Adverse reactions to drugs. BMJ 316:1511-1514.
125. Vlasses PH, Rotmensch HH, Ferguson RK, Sheaffer SL (1982). "Scalded mouth" caused by angiotensin-converting-enzyme inhibitors. Br Med J (Clin Res Ed) 284:1672-1673.
126. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ (1998). ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Safety 18:171-188.
127. Vondracek M, Xi Z, Larsson P, Baker V, Mace K, Pfeifer A, et al. (2001). Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis 22:481-488.
128. Weber MA (1988). Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med 84:16-23.
129. Weber MA (2001). Vasopeptidase inhibitors. Lancet 358:1525-1532.
130. Weber WW, Hein DW (1985). N-acetylation pharmacogenetics. Pharmacol Rev 37:25-79.
131. Weinshilboum RM, Otterness DM, Szumlansky CL (1999). Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
132. West AJ, Berger TG, LeBoit PE (1990). A comparative histopathologic study of photodistributed and nonphoto-distributed lichenoid drug eruptions. J Am Acad Dermatol 23:689-693.
133. Westbrook P, Bednarczyk EM, Carlson M, Sheehan H, Bissada NF (1997). Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. J Periodontol 68:645-650.
134. WHO Technical Report 498 (1972). (Available at www.who.int/tdr)
135. Wiesenfeld D, Scully C, MacFadyen EE (1982). Multiple lichenoid drug reactions in a patient with Ferguson-Smith disease. Oral Surg Oral Med Oral Pathol 54:527-529.
136. Wiholm BE, Emanuelsson S (1996). Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl 60:42-46.
137. Wintroub BU, Stern R (1985). Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol 13:167-179.
138. Wright P (1975). Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J 1:595-598.
139. Zhou LX, Pihlstrom B, Hardwick JP, Park SS, Wrighton SA, Holtzman JL (1996). Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin Pharmacol Ther 60:191-198.